Vivisight Completes Over RMB 100 Million Series B Financing to Accelerate Global Expansion and Disruptive Innovation of China's High-End Scientific Instruments

In the vastofIn the universe,ScienceThe instrument wasHailed asScientists'“Eyes”andLife Sciences Sector“The Pearl in the Crown”. There was a time when, in the scientific instrument market, foreign brands firmly controlled market discourse and captured over 90% of the market share by leveraging their technological accumulation and first-mover advantage. In recent years, however, this landscape has been quietly changing alongside the steady enhancement of China’s scientific research capabilities and the vigorous growth of domestic innovative enterprises.

Recently, an emerging industry star dedicated to the research and development of high-end biomedical equipment—Beijing Chaoweijing Biological Technology Co., Ltd. (hereinafter referred to as “TRANSCEND VIVOSCOPE”) announced the completion of its Series B financing round, exceeding RMB 100 million.This round of financing was led byCo-led by Fuxing Capital’s Star Future Fund, Shenzhen Capital Group’s Social Security Fund, and proprietary funds, with co-investment from Jiantou Investment Co., Ltd.. The funds raised will further support the company’s innovative R&D in high-end scientific instruments and innovative medical devices, as well as its market expansion both domestically and internationally, thereby accelerating its global layout.

As a representative of high-end domestically produced scientific instruments, TRANSCEND VIVOSCOPE is a commercialized outcome of the National Major Scientific Instrument Development Project funded by the National Natural Science Foundation of China, and was founded by the chief scientist of the “13th Five-Year Plan” National Biomedical Imaging Facility for Multimodal Cross-Scale Imaging,Academician Cheng Heping, Chinese Academy of SciencesLeadPeking University Interdisciplinary Team, officially founded in 2016.

Since its establishment, TRANSCEND VIVOSCOPE has remained focused on the high-end life science instrumentation and medical device industry, successively overcoming multiple core technologies,The only company globally with market-validated solutions for miniaturized multiphoton microscopy imaging systems, the company's high-end multimodal biomedical imaging platform canLife Sciences, Clinical Medicine, Aesthetic Medicine Research, Industrial Productionproviding professional solutions across multiple fields.

The research, development, and manufacturing of high-end scientific instruments demand exceptionally high technical standards and process precision. For a long time, domestically produced instruments have lagged behind their foreign counterparts in terms of technological sophistication and component quality. However, as the state places increasing emphasis on original innovation, the localization of scientific instruments has become a critical link in ensuring the autonomy and controllability of scientific and technological achievements. This is not only an intrinsic requirement for technological development but also a significant measure to enhance the nation’s overall competitiveness from the ground up.

The research and development of components for high-end scientific instruments spans multiple disciplines. To build a domestically sourced, closed-loop supply chain from the ground up, TRANSCEND VIVOSCOPE has assembled an interdisciplinary team led by Academician Cheng Heping, leveraging the resources of Peking University and the National Biomedical Imaging Facility.TeamThe team comprises leading experts across multiple disciplines, including optics, biology, electronics, translational medicine, and management, and holds independent intellectual property rights in foundational technologies within the fields of light, sound, and magnetism. Currently, through independent design and R&D, TRANSCEND VIVOSCOPE has achieved self-sufficiency and control over core components such as high-end lenses, specialty optical fibers, ultrafast lasers, and scanning devices.

These innovative achievements have not only broken the foreign technological monopoly and reduced reliance on imported components, but also mark a significant milestone for TRANSCEND VIVOSCOPE at the technical level,Achieved comprehensive self-sufficiency and controllability, spanning from the production of core components to the manufacturing of high-end scientific instruments and medical devices., providing a solid guarantee for the company's future high-quality development and setting a benchmark for the development of China's high-end scientific instrument industry.

Driven by top-down innovative breakthroughs, TRANSCEND VIVOSCOPE’s high-end multimodal biomedical imaging platform has demonstrated exceptional reliability and stability. To date, it hasAccumulated operating hours of tens of thousands. In terms of scientific research applications, it has been successfully completedHundreds of Experimental Projects, and has facilitated global scientists in publishingDozens of Top-Tier Scientific Research Articles, providing strong support for global basic research.

Established for nearly a decade, TRANSCEND VIVOSCOPE’s innovative achievements have been recognized as one of the “Top Ten Scientific Advances in China in 2017” and as *Nature Methods*’ “Method of the Year 2018,” and have beenNational MuseumPermanent Collection.Furthermore, the company is currently the only enterprise in China to have twice consecutively secured funding under the Ministry of Science and Technology’s National Key R&D Program for “Disruptive Technology Innovation Projects,” and was recognized as a national-level “Little Giant” firm specializing in refinement, differentiation, and innovation in 2024.

High-end scientific instruments are a crucial driving force for advancing fundamental research, and their scarcity is the root cause of China’s vulnerability to technological bottlenecks in numerous downstream key sectors. As a vital imaging technique in the field of biology, two-photon microscopy operates on the principle of laser interactions with molecules and atoms within biological tissues, which triggers the emission of fluorescent photons, thereby enabling fluorescence-based imaging to help usIn vivo, in situ, non-invasive, real-time, label-freeHistocytes were observed in the tissue.

However, traditional two-photon microscopy imaging technology faces numerous limitations in its widespread clinical adoption. On one hand, the bulky size of the imaging components and the overall equipment, coupled with inadequate ergonomic design, restricts the anatomical regions that can be examined during clinical use, thereby failing to meet diverse clinical needs. On the other hand, the complex and precise optical path structure within the internal space makes it challenging for traditionalDevice inSuboptimal performance in stability and reliability has hindered the broader application and expansion of this technology.

To break through these challenges, Academician Cheng Heping led his team in years of technological research and development. In 2017, TRANSCEND VIVOSCOPE successfully developed the probeHeavy2.2g ofUltra-High Spatiotemporal Resolution Miniaturized Two-Photon Microscope, significantly reducing the size and weight of the device, and obtaining, for the first time internationally, dynamic images of neuronal and synaptic activities in the cerebral cortex of mice during free behavior; in 2023, the team built on this success and developed a probe with onlyHeavy2.17 gMiniaturized Three-Photon Microscope, further breaking through the limits of imaging depth and achieving, for the first time, deep-brain dynamic functional imaging of neurons in the entire cerebral cortex and hippocampus of freely behaving mice, thereby providing robust technical support for in-depth exploration in neuroscience and related fields.

In addition, TRANSCEND VIVOSCOPE’s independently developedIn Vivo Two-Photon Microscopy Imaging SystemstillChina’s First Medical Device Based on Two-Photon Microscopy Imaging Principle to Obtain NMPA Registration CertificateThis system can significantly enhance the level of cellular imaging technology, presenting clearer and more precise image information to physicians. Meanwhile, it can be integrated with other diagnostic techniques to build a multimodal diagnostic system, providing more comprehensive and accurate solutions for clinical diagnosis.

The in vivo two-photon microscopy imaging system targets the clinical medical testing and diagnostics market, which is valued at hundreds of billions. Currently, the company is collaborating with leading domestic medical institutions and top-tier experts to promote the widespread clinical adoption of two-photon microscopy imaging technology, while also accelerating the establishment of new medical standards.

Currently, domestic scientific instrument enterprises are at a critical juncture for breakthrough. On one hand, they face the “chokehold” dilemma in core technologies and components, which urgently needs to be overcome; on the other hand, these companies are actively expanding into the global market to explore new business opportunities.

Against this backdrop, TRANSCEND VIVOSCOPE is actively expanding its global market presence. It has not only participated for two consecutive years in the world’s largest annual neuroscience conference—Society for Neuroscience (SfN) Annual Meeting, showcasing China’s latest breakthroughs and innovative achievements in the field of miniaturized multiphoton microscopy imaging technology to the global forefront. Moreover, in 2024, the company made its debut at Europe’s largest international neuroscience conference—Federation of European Neuroscience Societies (FENS), continuously advancing into the global high-end scientific instrument market.

Leveraging technological advantages and global operations,Company’s Miniaturized Multiphoton Imaging System Secures Overseas Orders Worth Tens of Millions of Yuan, including usersHarvard University, Johns Hopkins University, Stanford University, New York University, California Institute of Technology, Columbia University, Texas Medical Center, Max Planck Institute (Germany), Procter & Gamble Singapore Innovation Centerand leading universities and research institutes worldwide. By fostering broader international scientific collaboration and resource sharing, TRANSCEND VIVOSCOPE will provide stronger technological support for human health.

TRANSCEND VIVOSCOPE Co-Founder and CEO, Zhang GuoxiTRANSCEND VIVOSCOPE has long been committed to becoming a global leader in the field of biomedical imaging, having successfully established an end-to-end pipeline from concept to product to commercialization. By innovating life sciences technologies to create a better quality of life, TRANSCEND VIVOSCOPE provides innovative, high-quality, and systematic solutions to advance research and development in life sciences and medicine. The company has received support from multiple renowned investment institutions during this critical stage of its development, which will further drive high-quality growth and facilitate the industrial translation and application of cutting-edge innovative technologies. TRANSCEND VIVOSCOPE will also continue to pursue its global expansion strategy, empowering top-tier research institutions worldwide with high-end equipment under the “Intelligent Manufacturing in China” initiative, thereby contributing to the advancement of global life sciences research and the health and well-being of people everywhere.

Fosun Capital Star Future FundStatement: Fuxing Capital’s Star Future Fund places great emphasis on identifying and nurturing high-quality innovative enterprises in the healthcare sector. TRANSCEND VIVOSCOPE has achieved remarkable results in technological breakthroughs, establishing a closed-loop domestic supply chain, and scaling up production for overseas markets, demonstrating strong innovation capabilities and global competitiveness. With increased policy guidance and investment from the state in scientific instruments, healthcare, and life sciences research, TRANSCEND VIVOSCOPE is poised to seize significant development opportunities.

Fosun Health Capital’s Star Future Fund believes that miniaturized multiphoton microscopy enables in vivo, real-time, non-invasive functional imaging without the need for contrast agents, tissue staining, or tissue processing. With high sensitivity and subcellular resolution, this technology offers a novel approach to disease diagnosis in clinical medicine and holds broad application prospects. The fund is firmly optimistic about the future development of TRANSCEND VIVOSCOPE. Following the completion of its investment, Fosun Health Capital’s Star Future Fund will leverage Fosun Pharma’s industrial chain background and global investment layout to provide industrial synergy and empowerment support to TRANSCEND VIVOSCOPE, further facilitating its global expansion and jointly promoting the sustainable, high-quality development of the healthcare industry.

Shenzhen Capital Group and the National Social Security Fund Bay Area Sci-Tech Innovation FundIt is widely acknowledged that scientific instruments serve as the starting point for scientific research. China’s basic scientific instruments, particularly cutting-edge life science instruments, have long been monopolized by overseas brands. On January 15, 2025, the U.S. Department of Commerce imposed additional export controls on China, restricting the export of life science instruments capable of generating high-quality, high-content biological data. However, this dependency is now being broken. The team at TRANSCEND VIVOSCOPE represents a successful case where Chinese scientists and industrialization experts collaborated to transform globally leading scientific instruments from laboratory concepts into commercial products. After nearly a decade of refinement and accumulation, the company has entered a phase of rapid growth. We highly endorse the team’s product philosophy of “driven by scientific instruments, realized through medical devices,” and look forward to witnessing, under the leadership of Academician Cheng Heping and his team, the rise of China’s high-end scientific instruments and innovative medical device brands.

Xingweilai Fund is a fund under Fuxing Capital. Leveraging Fosun Pharma’s global medical device industrial foundation and high-tech advantages, it integrates domestic and international innovative medical technology resources to build a full-chain support system from R&D to commercialization. This initiative aims to optimize the industry chain, enhance innovation capabilities, cultivate healthcare enterprises with international competitiveness, and promote high-quality economic development.

Currently, the Star Future Fund focuses on investing in innovative enterprises in high-end medical devices, medical technology, and life sciences, introducing early-to-mid-stage projects in the broader health sector to promote the development of the biopharmaceutical and life health industries. The Star Future Fund not only provides financing support for emerging healthcare companies but also lays a strategic foundation for Fosun Pharma’s business expansion. Meanwhile, by integrating industrial resources with market demand, it injects new momentum into industrial upgrading and economic development.

Founded in 1999, Shenzhen Capital Group (SCGC) has adhered to the investment philosophy of “investing where the nation needs most.” Alongside the journey of self-reliance and strength across various industrial sectors in China, SCGC has become the industry leader and bellwether of venture capital in China. In 2024, SCGC began managing the National Social Security Fund’s Greater Bay Area Science and Technology Innovation Special Fund, further propelling Chinese high-tech enterprises into the deep waters of industrial development. Upholding its original aspiration to “discover and empower great enterprises,” SCGC continues to deepen its strategic layout in frontier technology fields, helping these companies stand out in fierce market competition and accelerating technological breakthroughs and commercial implementation.